Nicotine use and dependence is very high in patients with schizophrenia. One possible reason is that altered dopamine or glutamate activity in schizophrenia enhances the reinforcing effectiveness of nicotine. We used animal models to test the hypothesis that a hyperdopaminergic state (induced by repeated intermittent injections of amphetamine) or altered glutamate function (subchronic injection of phencyclidine, PCP) facilitates spontaneous acquisition of nicotine self-administration in rats. In Experiment 1 animals in an amphetamine-induced sensitized state (AISS) did not differ from saline-injected controls in their acquisition and maintenance of nicotine self-administration. This effect was replicated in experiment 2, but it was also found that AISS rats and saline-injected controls showed higher rates of nicotine self-administration compared to uninjected controls. This difference was maintained across several fixed ratio and progressive ratio schedules of reinforcement. In Experiment 3 PCP treated rats and their saline-injected controls did not differ in nicotine self-administration. However, both groups showed consistently increased responding for nicotine on FR and PR schedules compared to an uninjected control group. Injection-stress appeared to influence the outcomes of these experiments in two ways. Firstly, injection stress potentially masked the impact of the AISS and PCP treatment on nicotine self-administration. Secondly, injection stress itself may have been sufficient to induce plastic changes in dopamine and glutamate systems, and these changes enhanced the acquisition and maintenance of nicotine self-administration. Further investigation is needed into the role of stress in the development of nicotine use and dependence, in the aetiology of schizophrenia and in their co-morbidity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.schres.2017.02.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tobacco use is the leading cause of death globally and in the U.S. After decades of decline, driven by decreases in combusted tobacco use, nicotine product use has increased due to Electronic Nicotine Delivery Systems (ENDS), also known as e-cigarettes or vapes.
View Article and Find Full Text PDFUse of nicotine products, prescription drug products, and other methods to stop smoking by US adults in the 2022 National Health Interview Survey.
Intern Emerg Med
January 2025
Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY, USA.
Article Synopsis
- A recent CDC survey analyzed methods used by US adults to stop smoking, showing that around 2.9 million adults successfully quit for at least 6 months in the last year.
- Most successful quitters were younger, educated, male, non-Hispanic White, and commonly used nicotine products, especially e-cigarettes, compared to less popular options like prescription drugs.
- The study highlights that many adults still try to quit smoking without support, suggesting a need for targeted interventions to help those who struggle the most in quitting, using proven methods.
The role of glucocorticoid and nicotinic acetylcholine receptors in the reward-enhancing effects of nicotine in the ICSS procedure in male and female rats.
Drug Alcohol Depend
December 2024
Department of Psychiatry, University of Florida, Gainesville, FL, USA. Electronic address:
Tobacco use disorder is a chronic disorder that affects more than one billion people worldwide and causes the death of millions each year. The rewarding properties of nicotine are critical for the initiation of smoking. Previous research has shown that the activation of glucocorticoid receptors (GRs) plays a role in nicotine self-administration in rats.
View Article and Find Full Text PDFOral health risks in adults who use electronic nicotine delivery systems and oral nicotine pouches: a critical review of the literature and qualitative synthesis of the available evidence.
Harm Reduct J
December 2024
ABF Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstr. 5, 82152, Planegg, Germany.
Background: Use of combustible cigarettes (CCs) and smokeless oral tobacco products are well documented risk factors for a variety of oral diseases. However, the potential oral health risks of using recently introduced (since about 2000) non-combustible tobacco/nicotine products (NCPs: electronic cigarettes (ECs), heated tobacco products (HTPs) and oral nicotine pouches (ONPs), remain poorly established.
Methods: This review evaluates published human studies on detrimental oral health effects in people who use NCPs compared to those smoking cigarettes and those not using any tobacco/nicotine product (NU).
Validity of the E-Cigarette Wisconsin Inventory of Smoking Dependence Motives (e-WISDM) in Exclusive E-Cigarette Users: Evidence from a Laboratory Self-Administration Study.
Nicotine Tob Res
December 2024
Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Introduction: Prior research suggests that the e-Cigarette Wisconsin Inventory of Smoking Dependence Motives (e-WISDM) distinguishes primary (e-PDM) and secondary dependence (e-SDM), however, there is little research on these e-WISDM dimensions and prior research comprised dual users (using cigarettes and e-cigarettes) and those using older generations of e-cigarettes.
Methods: Those exclusively using contemporary e-cigarettes (N = 164) completed the e-WISDM and a laboratory self-administration session and rated pre-use expectancies and post-use experiences.
Results: Only a 1-factor model limited to the primary scales (Automaticity, Tolerance, Craving, Loss of Control) achieved good model fit.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!